Licensing and Partnerships in the Vaccine Field - The Fuel for Market Growth

Introduction

Due to the number and diversity of vaccine technologies and the high cost of product development, alliances and partnerships are becoming increasingly common in the vaccine sector. An analysis of the key biotech partnership opportunities at present is presented. 

Scope

Partnership selection criteria analysis 

Commentary on the drivers of vaccine alliances 

In depth analysis of the vaccine networks for the leading players in the market 

Report Highlights

Vaccine product success is heavily reliant on building strong relationships with health authorities and the organizers of immunization schedules. As such, smaller companies often seek partnership with one of the ‘big four’ vaccine giants, which explains, to some extent, the hive of licensing activity observed in this field 

Market growth and the introduction of higher value products has heightened the importance of best-practice in R&D, drug delivery and product manufacturing. Consequently, the success of key players will increasingly rely on their ability to establish and effectively manage complex vaccine networks 

Smaller vaccine companies looking for pharmaceutical partners should consider similar factors to those required in other sectors. However, additional issues, particularly manufacturing capability, should also be taken into account 

Reasons to Purchase

Understand the dynamics driving current vaccine licensing activity 

Determine which criteria are most important when selecting a partner or product to in-license 

Gain a clear picture of the vaccine networks established by key players and the benefits these infer 

Publisher: Datamonitor Infectious Diseases Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Infectious_Diseases.html#a177